Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation

A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function

(2017) Janna K. Duong et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency

(2016) E Luzon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis

(2016) Anyue Yin et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Personalized Drug Dosage – Closing the Loop

(2016) Geoffrey T Tucker   PHARMACEUTICAL RESEARCH

Population pharmacokinetics: an overview

(2016) Bruce Charles   Australian Prescriber

Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans

(2015) Nicolas Hohmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD

(2015) Simon J. C. Davies et al.   CLINICAL PHARMACOKINETICS

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

(2015) HM Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A proposal for scientific framework enabling specific population drug dosing recommendations

(2015) Pravin R. Jadhav et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The right dose for every patient: a key step for precision medicine

(2015) Richard W. Peck   NATURE REVIEWS DRUG DISCOVERY

PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways

(2014) M d L T Vieira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Abnormal olanzapine toxicokinetic profiles – population pharmacokinetic analysis

(2014) Zofia Tylutki et al.   TOXICOLOGY MECHANISMS AND METHODS

Influence ofCYP2C8polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomersin vitro

(2013) Lushan Yu et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

(2013) K-H Shin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility

(2013) Venkatesh Pilla Reddy et al.   SCHIZOPHRENIA RESEARCH

Predicted metabolic drug clearance with increasing adult age

(2012) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans

(2012) Vidya Perera et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Valproic Acid Significantly Lowers Serum Concentrations of Olanzapine—An Interaction Effect Comparable With Smoking

(2012) Tore Haslemo et al.   THERAPEUTIC DRUG MONITORING

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

(2011) Malcolm Rowland et al.   Annual Review of Pharmacology and Toxicology

The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy

(2011) Medine Idrizoglu Gulcebi et al.   EPILEPSY RESEARCH

Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics

(2011) Vidya Perera et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8

(2010) Hualin Jiang et al.   AMINO ACIDS

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

(2010) Xin-Sheng Lai et al.   CURRENT DRUG METABOLISM

Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects

(2010) S. B. Naraharisetti et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

(2010) M. Gertz et al.   DRUG METABOLISM AND DISPOSITION

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients

(2010) Roza Ghotbi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects onin vitroandin vivodrug–drug interactions

(2010) Yiwen Gao et al.   XENOBIOTICA

Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder

(2010) Evelyn D. Lobo et al.   PEDIATRIC DRUGS

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

(2009) Masoud Jamei et al.   Drug Metabolism and Pharmacokinetics

Assessment of inter-individual variability in predicted phenytoin clearance

(2009) Thomas M. Polasek et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics

(2009) Motohiro Nozawa et al.   THERAPEUTIC DRUG MONITORING

Functional Role of Ile264 in CYP2C8: Mutations Affect Haem Incorporation and Catalytic Activity

(2008) Rajinder Singh et al.   Drug Metabolism and Pharmacokinetics

Sex, Race, and Smoking Impact Olanzapine Exposure

(2008) Kristin L. Bigos et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

(2008) Helen E. Smith et al.   Pharmacogenetics and Genomics